Bristol licenses non-Rx drugs to Reckitt Benckiser for $482M

02/14/2013 | PharmaTimes (U.K.)

Reckitt Benckiser is paying $482 million for rights to market some of Bristol-Myers Squibb's nonprescription medications in Latin America. The three-year deal includes the painkiller Tempra, the antacid Picot, and cough and cold drug Naldecon. After three years, Reckitt Benckiser will be given the option to acquire legal rights and intellectual property for the treatments.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC